Selected research
Industry Growth & Trends
Global Avelumab Industry Growth and Trends Forecast to 2032
Market perspective
The global Avelumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Avelumab include Merck and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Avelumab market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Avelumab market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Avelumab market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Avelumab.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Avelumab market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Avelumab Market by Company
Merck
Pfizer
Avelumab Segment by Type
By Usage
By Specifications
Avelumab Segment by Application
Merkel-cell Carcinoma
Non-small Cell Lung Carcinoma (NSCLC)
Others
Avelumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avelumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Avelumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avelumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Avelumab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Avelumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Applications
- Merkel-cell Carcinoma
- Non-small Cell Lung Carcinoma (NSCLC)
- Others
Companies covered
- Merck
- Pfizer
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Avelumab Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Avelumab Sales Estimates and Forecasts (2021-2032)
- 1.3 Avelumab Market by Type
- 1.3.1 By Usage
- 1.3.2 By Specifications
- 1.4 Global Avelumab Market Size by Type
- 1.4.1 Global Avelumab Market Size Overview by Type (2021-2032)
- 1.4.2 Global Avelumab Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Avelumab Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Avelumab Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Avelumab Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Avelumab Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Avelumab Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Avelumab Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Avelumab Industry Trends
- 2.2 Avelumab Industry Drivers
- 2.3 Avelumab Industry Opportunities and Challenges
- 2.4 Avelumab Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Avelumab Revenue (2021-2026)
- 3.2 Global Top Players by Avelumab Sales (2021-2026)
- 3.3 Global Top Players by Avelumab Price (2021-2026)
- 3.4 Global Avelumab Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Avelumab Major Company Production Sites & Headquarters
- 3.6 Global Avelumab Company, Product Type & Application
- 3.7 Global Avelumab Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Avelumab Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Avelumab Players Market Share by Revenue in 2025
- 3.8.3 2025 Avelumab Tier 1, Tier 2, and Tier 3
4 Avelumab Regional Status and Outlook
- 4.1 Global Avelumab Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Avelumab Historic Market Size by Region
- 4.2.1 Global Avelumab Sales in Volume by Region (2021-2026)
- 4.2.2 Global Avelumab Sales in Value by Region (2021-2026)
- 4.2.3 Global Avelumab Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Avelumab Forecasted Market Size by Region
- 4.3.1 Global Avelumab Sales in Volume by Region (2027-2032)
- 4.3.2 Global Avelumab Sales in Value by Region (2027-2032)
- 4.3.3 Global Avelumab Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Avelumab by Application
- 5.1 Avelumab Market by Application
- 5.1.1 Merkel-cell Carcinoma
- 5.1.2 Non-small Cell Lung Carcinoma (NSCLC)
- 5.1.3 Others
- 5.2 Global Avelumab Market Size by Application
- 5.2.1 Global Avelumab Market Size Overview by Application (2021-2032)
- 5.2.2 Global Avelumab Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Avelumab Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Avelumab Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Avelumab Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Avelumab Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Avelumab Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Avelumab Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Avelumab Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Merck Avelumab Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer Avelumab Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Pfizer Avelumab Product Portfolio
- 6.2.5 Pfizer Recent Developments
7 North America by Country
- 7.1 North America Avelumab Sales by Country
- 7.1.1 North America Avelumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Avelumab Sales by Country (2021-2026)
- 7.1.3 North America Avelumab Sales Forecast by Country (2027-2032)
- 7.2 North America Avelumab Market Size by Country
- 7.2.1 North America Avelumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Avelumab Market Size by Country (2021-2026)
- 7.2.3 North America Avelumab Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Avelumab Sales by Country
- 8.1.1 Europe Avelumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Avelumab Sales by Country (2021-2026)
- 8.1.3 Europe Avelumab Sales Forecast by Country (2027-2032)
- 8.2 Europe Avelumab Market Size by Country
- 8.2.1 Europe Avelumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Avelumab Market Size by Country (2021-2026)
- 8.2.3 Europe Avelumab Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Avelumab Sales by Country
- 9.1.1 Asia-Pacific Avelumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Avelumab Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Avelumab Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Avelumab Market Size by Country
- 9.2.1 Asia-Pacific Avelumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Avelumab Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Avelumab Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Avelumab Sales by Country
- 10.1.1 South America Avelumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Avelumab Sales by Country (2021-2026)
- 10.1.3 South America Avelumab Sales Forecast by Country (2027-2032)
- 10.2 South America Avelumab Market Size by Country
- 10.2.1 South America Avelumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Avelumab Market Size by Country (2021-2026)
- 10.2.3 South America Avelumab Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Avelumab Sales by Country
- 11.1.1 Middle East and Africa Avelumab Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Avelumab Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Avelumab Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Avelumab Market Size by Country
- 11.2.1 Middle East and Africa Avelumab Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Avelumab Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Avelumab Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Avelumab Value Chain Analysis
- 12.1.1 Avelumab Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Avelumab Production Mode & Process
- 12.2 Avelumab Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Avelumab Distributors
- 12.2.3 Avelumab Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst